Gene therapy startup Rocket Pharma reverse merges with troubled Inotek after $25M raise

Two months after Inotek shares cratered following the second conclusive failure of its lead glaucoma drug — scuttling its share price — the Lexington, MA-based biotech $ITEK has become a reverse merger shell for a gene therapy company called Rocket Pharmaceuticals.

Inotek CEO David Southwell said the reverse merger was the best option for shareholders, who will wind up with a 19% slice of the merged operation. Just before the announcement, Inotek stock ended the day at $1.05 and a market cap of $28 million — far less than cash.

Gaurav Shah

Rocket has kept a low profile, but it’s headed by Novartis vet Gaurav Shah, a Columbia-educated physician who spent several years working on the pharma giant’s breakthrough CAR-T program, according to his LinkedIn profile. Earlier this year Rocket filed a Form D with the SEC stating that it had raised $25 million of a $30 million round.

That filing included Naveen Yalamanchi at RTW as a principal, alongside his colleague Roderick Wong and Shah.

Rocket now emerges with a spot on the public markets and a focus on developing gene therapies with a pair of vector platforms to its credit. According to a report in Xconomy last year, Rocket has helped fund the research of Fred Hutch investigator Jennifer Adair, who’s been working on a bench top gene therapy system that could be used in the field, so to speak.

“Our vision is to create a fully-integrated platform gene therapy company with a portfolio of distinct treatments for devastating genetic diseases,” said Shah in a statement. “FA, LAD-1 and PKD are near term opportunities in rare bone marrow-derived disorders. The AAV-based approach, while earlier, will target treatment of a broader range of challenging diseases.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->